<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11430">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00574912</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#060887-Lantus Glargine</org_study_id>
    <secondary_id>VUMC 32787</secondary_id>
    <nct_id>NCT00574912</nct_id>
  </id_info>
  <brief_title>Characteristics of Glargine in Type 2 Diabetics</brief_title>
  <official_title>A Comparison of PK/PD Dose Response Characteristics of Glargine in Type 2 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to determine the dose response relationship of insulin glargine in type 2
      diabetes over a 24-hour period and measuring the differences in glucose production among the
      differing doses of glargine.

      Hypothesis: Differing doses of insulin glargine over a 24-hour period in type 2 diabetes
      will show differing effects on endogenous glucose production, glucose disposal and
      carbohydrate and lipid flux.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The incidence of type 2 DM is increasing worldwide at an alarming rate. Unfortunately, the
      number of individuals with glycemic control at or below the American Diabetes Association
      goal of 7% has dropped. In fact, the number of patients with their important cardiometabolic
      risk factors of glucose, lipids and blood pressure at goal is only 7%. One of the reasons
      for this lack of metabolic control in type 2 DM is the continued relative underutilization
      of insulin. Diabetes is an insulin deficient state and requires appropriate physiologic
      replacement of insulin. Physiologic replacement of insulin requires a basal component to
      restrain overnight endogenous glucose production, lipolysis and proteolysis. The other
      component involves prandial insulin to regulate post prandial glucose levels. Recently,
      insulin glargine was introduced as a once-a-day peakless basal insulin. This form of basal
      insulin reproduces the normal constitutive physiologic release of insulin from the pancreas.
      Insulin glargine represents a breakthrough in treatment as the previous available &quot;basal
      insulins&quot; either produced peaks of activity (which are disadvantageous as this results in
      hypoglycemia) or do not last 24 hrs which results in post absorbative hyperglycemia. Despite
      the undoubted advantages of insulin glargine, there remains a lack of information regarding
      some aspects of glargine action. The study objectives are: 1) to determine the
      pharmacokinetic and pharmacodynamic dose response relationship of insulin glargine in Type 2
      DM; 2) partition the dose response relationship of insulin glargine on endogenous glucose
      production and glucose uptake in Type 2 DM; and 3) to determine if the pharmacokinetic and
      pharmacodynamics of insulin glargine are consistent over a wide range of doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Glucose Infusion Rate</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1--All interventions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participant will be given all 5 interventions in the same order
Placebo, then
0.5 units of Glargine/kg body weight then,
1.0 units of Glargine/kg body weight, then
1.5 units of Glargine/kg body weight, then
2.0 units of Glargine/kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo or Insulin Glargine</intervention_name>
    <description>administering single dose of Placebo injected s/c at 8am and monitoring blood glucose over 24 hours, then 8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)</description>
    <arm_group_label>1--All interventions</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12 adults (males or females) with type 2 diabetes for at least six (6) months. May be
             using oral agents (SUs, metformin, acarbose or glitinides) with or without insulin.

          -  HgbA1c 7 -12%

          -  Age 18-70 years

          -  BMI 27-40 kg/mÂ²

        Exclusion Criteria:

          -  Any past or present clinically relevant abnormality, medical condition, or
             circumstance making the subject unsuitable for participation in the study

          -  Evidence of hepatic, renal or cardiac failure

          -  Abnormal results following screening tests

          -  Pregnant or lactating females or females of childbearing potential who are unwilling
             to abstain from sexual intercourse or use reliable, medically accepted methods of
             contraception

          -  Currently using TZDs

          -  History of alcoholism or drug abuse within 12 months of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N. Davis, MD, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 2, 2015</lastchanged_date>
  <firstreceived_date>December 13, 2007</firstreceived_date>
  <firstreceived_results_date>December 18, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Chairman of Medicine, University of Maryland, Baltimore</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin Glargine</keyword>
  <keyword>Endogenous Glucose Production</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glargine</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>12 individuals will be their own controls completing 5 separate 24 hour protocol studies. If a participant does not complete all protocols, another person will be recruited to complete the protocols until there are 12 completed studies in each arm/group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1 All Interventions</title>
          <description>Other: 1--All interventions
All participant will be given all 5 interventions in the same order
Placebo, then 0.5 units of Glargine/kg body weight, then 1.0 units of Glargine/kg body weight, then 1.5 units of Glargine/kg body weight, then 2.0 units of Glargine/kg body weight,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Placebo</title>
              <participants_list>
                <participants group_id="P1" count="12">12 original participants started the trial.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 0.5</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1.0</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 1.5</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 2.0</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not place IV lines.</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>scheduling conflicts</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One group of participants may have participated in more than one arm/group.</population>
      <group_list>
        <group group_id="B1">
          <title>1--All Interventions</title>
          <description>Arm: Other: 1--All interventions
All participant will be given all 5 interventions in the same order
Placebo, then 0.5 units of Glargine/kg body weight, then 1.0 units of Glargine/kg body weight, then 1.5 units of Glargine/kg body weight, then 2.0 units of Glargine/kg body weight,</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50" spread="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Infusion Rate</title>
        <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>12 participants in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>1/0.0 Placebo</title>
            <description>Maximum glucose infusion rate</description>
          </group>
          <group group_id="O2">
            <title>2/0.5 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O3">
            <title>3/1.0 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O4">
            <title>4/1.5 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
          <group group_id="O5">
            <title>5/2.0 Units of Glargine/kg</title>
            <description>maximum glucose infusion rate</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="12"/>
                  <measurement group_id="O4" value="12"/>
                  <measurement group_id="O5" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Glucose Infusion Rate</title>
            <description>measuring the changes in glucose infusion rate during the 24 hour experimental period.</description>
            <units>umol/kg/min</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="0.3"/>
                  <measurement group_id="O2" value="2.6" spread="0.9"/>
                  <measurement group_id="O3" value="5.5" spread="1.5"/>
                  <measurement group_id="O4" value="6.8" spread="2.0"/>
                  <measurement group_id="O5" value="9.5" spread="2.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1/0.0</title>
          <description>Placebo
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E2">
          <title>2/0.5</title>
          <description>0.5 units of Glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E3">
          <title>3/1.0</title>
          <description>1 unit of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E4">
          <title>4/1.5</title>
          <description>1.5 units of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
        <group group_id="E5">
          <title>5/2.0</title>
          <description>2.0 units of glargine/kg body weight
Insulin Glargine: administering single, differing dose of insulin glargine over a 24 hour period every 8 weeks times five</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen N. Davis</name_or_title>
      <organization>University of Maryland, Baltimore</organization>
      <phone>4103282488</phone>
      <email>sdavis@medicine.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
